Loading…
Protara Therapeutics, Inc. is projected to rise to $5.02 by 2027, a +28% move from its current price of $3.92. TARA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.82 | $3.92 | $4.02 | +0.05% |
| Aug 4 | $3.78 | $3.92 | $4.07 | +0.11% |
| Aug 5 | $3.76 | $3.93 | $4.10 | +0.16% |
| Aug 6 | $3.73 | $3.93 | $4.13 | +0.22% |
| Aug 7 | $3.71 | $3.93 | $4.16 | +0.27% |
| Aug 8 | $3.69 | $3.93 | $4.19 | +0.32% |
| Aug 9 | $3.68 | $3.93 | $4.21 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.68 | $3.93 | $4.21 | +0.38% |
| Week 2 | $3.59 | $3.95 | $4.35 | +0.76% |
| Week 3 | $3.53 | $3.96 | $4.46 | +1.14% |
| Week 4 | $3.48 | $3.98 | $4.56 | +1.52% |
| Week 5 | $3.43 | $3.99 | $4.65 | +1.91% |
| Week 6 | $3.40 | $4.01 | $4.73 | +2.29% |
| Week 7 | $3.36 | $4.03 | $4.81 | +2.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for cancer and rare diseases. Its lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Protara Therapeutics operates in the Healthcare category and centers its work on developing therapies with the potential to address unmet medical needs. The description highlights its clinical-stage status and its dual-path approach in oncology and supportive care to patients on parenteral nutrition.
These facts establish Protara Therapeutics as a healthcare-focused, early-stage biopharma with ongoing programs and a New York headquarters, positioning it within the clinical development landscape for cancer and rare diseases.
Protara Therapeutics, Inc. trades under the symbol TARA. The stock sits in the Healthcare sector as a clinical-stage biopharmaceutical company.
The current price is $3.81 with a market capitalization of $214.14M and a market rank of 3747, reflecting a relatively small-cap, early-stage profile within the market.
The long-run outlook in the provided forecast is bullish, with expected upside in multiple future years and sizable ROIs, including a 2050 estimate of $23.46 average price and a 515.7% ROI, signaling meaningful potential appreciation if forecasts materialize.
In the near term, the stock faces a bearish technical backdrop despite the long-run upside potential, underscoring the distinct difference between current price action and longer-horizon forecasts.
A major floor 10.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.8% away) — a key level to hold.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 44.4% above — clearing it would confirm fresh momentum.
Key TARA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TARA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.95 | Sell | $3.96 | Sell |
| MA 10 | $4.00 | Sell | $3.99 | Sell |
| MA 20 | $4.08 | Sell | $4.04 | Sell |
| MA 50 | $4.17 | Sell | $4.25 | Sell |
| MA 100 | $4.69 | Sell | $4.59 | Sell |
| MA 200 | $5.28 | Sell | $4.74 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.47 | Neutral |
| Stoch RSI (14) | 61.03 | Neutral |
| CCI (20) | -138.82 | Sell |
| Williams %R (14) | -64.52 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -4.85 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 35.48 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 38.10 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.89 | Buy |
| ADX (14) | 11.55 | Neutral |
| ATR (14) | 0.09 | Info |
The near-term picture is BEARISH according to the latest technical inputs. The RSI(14) is 40, indicating modest downside momentum, while the 50-day simple moving average sits at $4.19 and the 200-day simple moving average at $5.30.
Support is listed at $3.81 and resistance at $4.32, placing the current price close to the support level. The 30-day range spans from a low of $3.26 to a high of $4.46, illustrating a relatively tight trading band around the $3.8 area.
Overall, the technical setup points to nearby pressure with a defined support, while longer-term forecasts imply higher potential further out if catalysts align.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.65 | $3.92 | $5.09 | 0% | Neutral | |
| $4.02 | $5.02 | $6.60 | +28% | Bullish | |
| $4.42 | $5.66 | $7.71 | +44% | Bullish | |
| $4.66 | $6.10 | $8.55 | +56% | Bullish | |
| $4.61 | $6.15 | $8.82 | +57% | Bullish | |
| $4.80 | $6.52 | $9.54 | +66% | Bullish | |
| $5.06 | $6.98 | $10.40 | +78% | Bullish | |
| $5.52 | $7.73 | $11.71 | +97% | Bullish | |
| $6.46 | $9.17 | $14.11 | +134% | Bullish | |
| $6.90 | $9.93 | $15.49 | +153% | Bullish | |
| $8.73 | $13.36 | $22.11 | +241% | Bullish | |
| $15.16 | $25.79 | $46.54 | +558% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.65 | $3.92 | $4.70 | +0.00% |
| September 2026 | $3.45 | $4.07 | $4.93 | +3.80% |
| October 2026 | $3.47 | $4.12 | $5.04 | +1.20% |
| November 2026 | $3.38 | $4.03 | $4.98 | -2.07% |
| December 2026 | $3.41 | $4.09 | $5.09 | +1.48% |
Click any year to see its month-by-month TARA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TARA price prediction for 2026 points to an average of $3.92 (low $3.65, high $5.09) — a potential gain of 0% on today's $3.92. A consolidation phase looks the most probable path here.
In 2027, TARA is projected to trade between $4.02 and $6.60, averaging $5.02 — a potential gain of +28% from today's $3.92. That is up +28% on the projected 2026 average. Momentum favours further upside here.
Protara Therapeutics, Inc.'s 2028 outlook centres on $5.66, within a $4.42 to $7.71 range. That is up +13% on the projected 2027 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, TARA could reach as high as $8.55, with a base case around $6.10 and support toward $4.66 — roughly +56% from $3.92. Momentum favours further upside here.
Expect TARA to range from $4.61 to $8.82 through 2030. The $6.15 average target implies a +57% move from current prices. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The TARA price prediction for 2031 points to an average of $6.52 (low $4.80, high $9.54) — a potential gain of +66% on today's $3.92. Momentum favours further upside here.
In 2032, TARA is projected to trade between $5.06 and $10.40, averaging $6.98 — a potential gain of +78% from today's $3.92. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Protara Therapeutics, Inc.'s 2033 outlook centres on $7.73, within a $5.52 to $11.71 range. That is up +11% on the projected 2032 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2034, TARA could reach as high as $14.11, with a base case around $9.17 and support toward $6.46 — roughly +134% from $3.92. Buyers look set to stay in control over this stretch.
Expect TARA to range from $6.90 to $15.49 through 2035. The $9.93 average target implies a +153% move from current prices. That is up +8% on the projected 2034 average. Momentum favours further upside here.
The TARA price prediction for 2040 points to an average of $13.36 (low $8.73, high $22.11) — a potential gain of +241% on today's $3.92. Buyers look set to stay in control over this stretch.
In 2050, TARA is projected to trade between $15.16 and $46.54, averaging $25.79 — a potential gain of +558% from today's $3.92. That is up +93% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TARA today (≈ 255.102041 TARA) could be worth
$6,578.46
+$5,578.46 (+558%) by 2050 · US Dollar
Based on the average projected TARA price of $25.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TARAwould be worth at today's price.
$1,000 invested in TARA on Jul 31, 2025 (≈ 322.580655 TARA) would be worth
$1,264.52
+$264.52 (+26.5%) today · 1.26× · US Dollar
Based on a TARA entry price of $3.1 vs. today's $3.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.02 | $975.12 | -2.5% |
| 1 month ago | $4.04 | $970.3 | -3.0% |
| 3 months ago | $5.32 | $736.84 | -26.3% |
| 6 months ago | $7.04 | $556.82 | -44.3% |
| 1 year ago | $3.1 | $1,264.52 | +26.5% |
| All time (5.0y) ago | $7.8 | $502.56 | -49.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TARA forecast.
Our base-case forecast reaches $7.80 around 2034.
Implied market cap at $7.80: $438.39M
The multi-year forecast shows a clear uptrend in expected prices and returns, with the 2026 average price at $3.81 and a neutral sentiment state. From 2027 onward, the outlook turns bullish, with the average price rising to $4.79 in 2027 and continuing higher in later years.
2030 presents an average price of $5.82 with a max of $8.24 and a minimum of $4.41, delivering a 52.8% ROI and a bullish sentiment. The trajectory continues to 2040, where the average reaches $12.18, the max $19.74, and the ROI climbs to 219.6% with a bullish stance. By 2050, the forecast envisions a min of $14.25, an average of $23.46, and a max of $41.29, accompanied by a 515.7% ROI and bullish sentiment.
These figures imply meaningful long-term appreciation potential, tempered by the near-term bearish setup and the inherent uncertainty of clinical-stage development timelines. The drivers noted by the forecast include ongoing development activity in TARA-002 and related pipeline progress, while risks include execution, clinical outcomes, and funding dynamics that can influence realization of the projected upside.
Tap a question to reveal the answer.
2030 forecast: min $4.41, avg $5.82, max $8.24, ROI 52.8%, sentiment BULLISH.
The near term shows BEARISH momentum, but the longer-term forecast is BULLISH with rising averages and ROIs reaching 52.8% by 2030 and 515.7% by 2050. Current price is $3.81 with a market cap of $214.14M and rank 3747; forecasts are estimates, not guarantees.
Forecasts indicate potential to surpass $10, with 2033 min $5.21, avg $7.19, max $10.71 (ROI 88.6%), and 2034 max $12.79 (ROI 121.9%), within a bullish long-run trajectory.
Current price is $3.81. The 30-day range is $3.26 to $4.46, with support at $3.81 and resistance at $4.32.
2050 forecast: min $14.25, avg $23.46, max $41.29, ROI 515.7%, sentiment BULLISH.
Protara Therapeutics, Inc. Community Discussion
0Share your Protara Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.